Aclaris Therapeutics (ACRS) Current Deferred Revenue (2024 - 2026)

Aclaris Therapeutics' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 2.16% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (up 2.16% YoY), while the FY2025 annual figure was $3.9 million, up 1.36% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $4.0 million, up from $3.9 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $25.8 million in Q2 2024, with the low at $3.8 million in Q3 2024.
• The 3-year median for Current Deferred Revenue is $3.9 million (2025), against an average of $6.6 million.
• Peak annual rise in Current Deferred Revenue reached 4.25% in 2025, while the deepest fall reached 84.83% in 2025.
• Aclaris Therapeutics' Current Deferred Revenue stood at $3.9 million in 2024, then gained by 1.36% to $3.9 million in 2025, then rose by 0.74% to $4.0 million in 2026.
• Business Quant data shows ACRS's Current Deferred Revenue at $4.0 million in Q1 2026, $3.9 million in Q4 2025, and $3.9 million in Q3 2025.